Immunic, Inc. IMUX
We take great care to ensure that the data presented and summarized in this overview for IMMUNIC, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding IMUX
View all-
Abrdn PLC8.24MShares$6.18 Million0.01% of portfolio
-
Bvf Inc San Francisco, CA7.65MShares$5.74 Million0.35% of portfolio
-
Avidity Partners Management LP Dallas, TX4.7MShares$3.52 Million2.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.35MShares$3.26 Million0.0% of portfolio
-
Morgan Stanley New York, NY3.1MShares$2.33 Million0.0% of portfolio
-
Gratus Capital LLC2.11MShares$1.58 Million0.1% of portfolio
-
Laurion Capital Management LP New York, NY1.88MShares$1.41 Million0.03% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT1.58MShares$1.19 Million0.08% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA1.4MShares$1.05 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.03MShares$775,3290.0% of portfolio
Latest Institutional Activity in IMUX
Top Purchases
Top Sells
About IMUX
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.
Insider Transactions at IMUX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 13
2025
|
Duane Nash Executive Chairman |
BUY
Open market or private purchase
|
Direct |
20,000
+35.69%
|
$0
$0.83 P/Share
|
|
Jun 05
2025
|
Jason Tardio President and COO |
BUY
Open market or private purchase
|
Direct |
12,512
+50.0%
|
$0
$0.79 P/Share
|
|
Jun 05
2025
|
Joerg Neermann Director |
BUY
Open market or private purchase
|
Direct |
30,000
+13.04%
|
$0
$0.76 P/Share
|
|
Jun 04
2025
|
Daniel Vitt CEO and Director |
BUY
Open market or private purchase
|
Direct |
15,000
+34.09%
|
$0
$0.77 P/Share
|
|
Jun 04
2025
|
Joerg Neermann Director |
BUY
Open market or private purchase
|
Direct |
70,000
+29.17%
|
$0
$0.77 P/Share
|
|
Jun 03
2025
|
Glenn Whaley Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
45,000
+32.03%
|
$0
$0.71 P/Share
|
|
Jun 03
2025
|
Richard Alan Rudick Director |
BUY
Open market or private purchase
|
Direct |
143,075
+38.31%
|
$0
$0.7 P/Share
|
|
May 30
2025
|
Glenn Whaley Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+33.11%
|
$0
$0.56 P/Share
|
|
Nov 12
2024
|
Richard Alan Rudick Director |
BUY
Open market or private purchase
|
Direct |
87,300
+50.0%
|
$87,300
$1.15 P/Share
|
|
Feb 26
2024
|
Daniel Vitt CEO and Director |
BUY
Open market or private purchase
|
Indirect |
14,000
+3.46%
|
$14,000
$1.31 P/Share
|
|
May 15
2023
|
Glenn Whaley Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+16.39%
|
$5,000
$1.75 P/Share
|
|
Dec 14
2022
|
Joerg Neermann Director |
BUY
Open market or private purchase
|
Direct |
47,000
+31.97%
|
$47,000
$1.26 P/Share
|
|
Dec 13
2022
|
Joerg Neermann Director |
BUY
Open market or private purchase
|
Direct |
35,000
+39.77%
|
$35,000
$1.25 P/Share
|
|
Nov 23
2022
|
Joerg Neermann Director |
BUY
Open market or private purchase
|
Direct |
18,000
+50.0%
|
$18,000
$1.39 P/Share
|
|
Nov 22
2022
|
Daniel Vitt CEO and Director |
BUY
Open market or private purchase
|
Indirect |
8,000
+2.08%
|
$8,000
$1.35 P/Share
|
|
Nov 07
2022
|
Glenn Whaley Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+19.6%
|
$5,000
$1.5 P/Share
|
|
Jun 03
2022
|
Glenn Whaley Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
3,500
+21.78%
|
$10,500
$3.04 P/Share
|
|
Jun 03
2022
|
Daniel Vitt CEO and Director |
BUY
Open market or private purchase
|
Indirect |
5,000
+1.34%
|
$15,000
$3.1 P/Share
|
|
May 12
2022
|
Andreas Muehler Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
3,500
+1.16%
|
$17,500
$5.1 P/Share
|
|
May 12
2022
|
Duane Nash Executive Chairman |
SELL
Bona fide gift
|
Direct |
6,000
-27.23%
|
-
|
Last 12 Months Summary
| Open market or private purchase | 423K shares |
|---|---|
| Grant, award, or other acquisition | 25K shares |